If some of the rumblings about the last stock offering are true, then a short isn't too bad a move.
I don't think MTC approval should have much of an impact on the share price. If they're able to get 10 million or so in sales next year then at least it'll put in a decent floor on the share price while we wait for prostate and melanoma news.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.